Lytix Biopharma is pleased to announce that the 2nd cohort of LTX-315 (4 mg) in combination with anti-PD1 treatment (pembrolizumab) is completed.

Three patients completed all planned 3 weeks of LTX-315 treatment in combination with pembrolizumab with no clinically significant LTX-315 related adverse events or dose-limiting toxicities observed. A new, higher dose (5 mg) cohort in TNBC was opened June 28th.